Form 4: Fennec Pharmaceuticals CEO Hackman Increases Stake in Company
SEC Form 4 Filing
Fennec Pharmaceuticals CEO Jeffrey S. Hackman reports purchasing additional company shares on May 16 and May 19, 2025.
Summary
- On May 16, 2025, Jeffrey S. Hackman, CEO of Fennec Pharmaceuticals, purchased 1,035 common shares at $6.75 per share.
- On May 19, 2025, Mr. Hackman purchased an additional 13,965 common shares at $6.99 per share.
- Following these transactions, Mr. Hackman directly owns 15,000 common shares of Fennec Pharmaceuticals.
Sentiment
Score: 7
Explanation: The sentiment is moderately positive as the CEO is increasing their stake in the company, which is generally viewed favorably by investors.
Positives
- The CEO's purchase of shares may signal confidence in the company's future prospects.
Industry Context
Insider buying is often seen as a positive sign, suggesting that a company's leadership believes the stock is undervalued.
Stakeholder Impact
- Shareholders may view the CEO's stock purchases as a positive signal.
Key Dates
| Date | Description |
|---|---|
| 05/16/2025 | CEO purchased 1,035 common shares at $6.75 per share. |
| 05/19/2025 | CEO purchased 13,965 common shares at $6.99 per share; Form 4 filing date. |
Keywords
Fennec Pharmaceuticals, Jeffrey Hackman, insider trading, stock purchase, Form 4, FENC, CEO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.